ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although imatinib effectively inhibits BCR-ABL kinase and downstream signaling pathways in stem-like CML cells, it does not induce cell death in vitro, suggesting LSCs are resistant to TKI treatment (40).